Medifast Free Cash Flow (FCF) History (MED)
Medifast reported $1.2M in free cash flow for fiscal 2025, a decrease of 92.66% from the previous fiscal year, with a free cash flow margin of 0.32%.
View full Medifast company overviewMedifast free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.2M | −$15.8M | −92.66% | +0.32% |
| 2024 | 2024-12-31 | $17.0M | −$124.2M | −87.94% | +2.83% |
| 2023 | 2023-12-31 | $141.2M | −$36.7M | −20.64% | +13.17% |
| 2022 | 2022-12-31 | $177.9M | $117.6M | +194.83% | +11.13% |
| 2021 | 2021-12-31 | $60.3M | −$79.0M | −56.69% | +3.95% |
| 2020 | 2020-12-31 | $139.3M | $65.1M | +87.74% | +14.90% |
| 2019 | 2019-12-31 | $74.2M | $18.3M | +32.80% | +10.40% |
| 2018 | 2018-12-31 | $55.9M | $15.9M | +39.71% | +11.15% |
| 2017 | 2017-12-31 | $40.0M | $17.5M | +77.96% | +13.26% |
| 2016 | 2016-12-31 | $22.5M | −$4.1M | −15.49% | +8.19% |
| 2015 | 2015-12-31 | $26.6M | $8.1M | +43.65% | +9.75% |
| 2014 | 2014-12-31 | $18.5M | −$12.5M | −40.23% | +6.49% |
| 2013 | 2013-12-31 | $31.0M | −$1.2M | −3.62% | +9.56% |
| 2012 | 2012-12-31 | $32.1M | $11.5M | +56.03% | +10.09% |
| 2011 | 2011-12-31 | $20.6M | $3.9M | +23.23% | +6.91% |
| 2010 | 2010-12-31 | $16.7M | $2.7M | +19.06% | +6.49% |
| 2009 | 2009-12-31 | $14.0M | — | — | +8.27% |
Medifast quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $728,000 | $5.5M | — | +0.95% |
| Q1 2026 | 2026-03-31 | −$836,000 | −$2.7M | — | −1.10% |
| Q4 2025 | 2025-12-31 | −$6.6M | $603,000 | — | −8.83% |
| Q3 2025 | 2025-09-30 | $10.8M | $3.1M | +39.94% | +12.02% |
| Q2 2025 | 2025-06-30 | −$4.8M | −$15.9M | — | −4.51% |
| Q1 2025 | 2025-03-31 | $1.9M | −$3.6M | −65.37% | +1.63% |
| Q4 2024 | 2024-12-31 | −$7.2M | −$16.8M | — | −6.08% |
| Q3 2024 | 2024-09-30 | $7.7M | −$20.6M | −72.81% | +5.48% |
| Q2 2024 | 2024-06-30 | $11.1M | −$30.3M | −73.11% | +6.60% |
| Q1 2024 | 2024-03-31 | $5.4M | −$56.5M | −91.22% | +3.11% |
| Q4 2023 | 2023-12-31 | $9.6M | −$33.1M | −77.56% | +5.01% |
| Q3 2023 | 2023-09-30 | $28.3M | −$25.4M | −47.32% | +11.98% |
| Q2 2023 | 2023-06-30 | $41.4M | $480,000 | +1.17% | +13.98% |
| Q1 2023 | 2023-03-31 | $61.9M | $21.3M | +52.33% | +17.75% |
| Q4 2022 | 2022-12-31 | $42.7M | $61.8M | — | +12.65% |
| Q3 2022 | 2022-09-30 | $53.6M | $48.2M | +891.09% | +13.74% |
| Q2 2022 | 2022-06-30 | $40.9M | $27.6M | +208.15% | +9.03% |
| Q1 2022 | 2022-03-31 | $40.7M | −$20.1M | −33.04% | +9.74% |
| Q4 2021 | 2021-12-31 | −$19.1M | −$36.9M | — | −5.05% |
| Q3 2021 | 2021-09-30 | $5.4M | −$32.4M | −85.70% | +1.31% |
| Q2 2021 | 2021-06-30 | $13.3M | −$43.9M | −76.79% | +3.37% |
| Q1 2021 | 2021-03-31 | $60.7M | $34.3M | +129.67% | +17.83% |
| Q4 2020 | 2020-12-31 | $17.8M | −$524,000 | −2.86% | +6.72% |
| Q3 2020 | 2020-09-30 | $37.8M | $22.2M | +141.90% | +13.94% |
| Q2 2020 | 2020-06-30 | $57.2M | $45.3M | +378.90% | +26.01% |
| Q1 2020 | 2020-03-31 | $26.4M | −$1.8M | −6.54% | +14.82% |
| Q4 2019 | 2019-12-31 | $18.3M | $4.7M | +34.26% | +10.74% |
| Q3 2019 | 2019-09-30 | $15.6M | $9.8M | +169.97% | +8.23% |
| Q2 2019 | 2019-06-30 | $11.9M | −$7.8M | −39.39% | +6.39% |
| Q1 2019 | 2019-03-31 | $28.3M | $11.6M | +69.18% | +17.05% |
| Q4 2018 | 2018-12-31 | $13.6M | $4.5M | +49.61% | +9.36% |
| Q3 2018 | 2018-09-30 | $5.8M | −$5.4M | −48.01% | +4.16% |
| Q2 2018 | 2018-06-30 | $19.7M | $6.2M | +45.86% | +16.80% |
| Q1 2018 | 2018-03-31 | $16.7M | $10.5M | +169.15% | +16.96% |
| Q4 2017 | 2017-12-31 | $9.1M | $10.3M | — | +11.69% |
| Q3 2017 | 2017-09-30 | $11.1M | $5.5M | +97.10% | +14.44% |
| Q2 2017 | 2017-06-30 | $13.5M | $3.1M | +30.12% | +17.85% |
| Q1 2017 | 2017-03-31 | $6.2M | −$1.4M | −18.08% | +8.80% |
| Q4 2016 | 2016-12-31 | −$1.2M | −$2.1M | — | −1.84% |
| Q3 2016 | 2016-09-30 | $5.7M | −$3.6M | −38.71% | +8.25% |
| Q2 2016 | 2016-06-30 | $10.4M | $3.1M | +42.80% | +14.60% |
| Q1 2016 | 2016-03-31 | $7.6M | −$1.6M | −17.48% | +10.48% |
| Q4 2015 | 2015-12-31 | $900,000 | $2.8M | — | +1.47% |
| Q3 2015 | 2015-09-30 | $9.2M | $2.2M | +30.44% | +13.99% |
| Q2 2015 | 2015-06-30 | $7.3M | $3.3M | +85.23% | +10.08% |
| Q1 2015 | 2015-03-31 | $9.2M | −$248,000 | −2.63% | +12.53% |
| Q4 2014 | 2014-12-31 | −$1.9M | −$7.5M | — | −3.09% |
| Q3 2014 | 2014-09-30 | $7.1M | $3.8M | +113.78% | +10.25% |
| Q2 2014 | 2014-06-30 | $3.9M | −$6.0M | −60.31% | +5.25% |
| Q1 2014 | 2014-03-31 | $9.4M | −$2.8M | −22.92% | +11.91% |
| Q4 2013 | 2013-12-31 | $5.5M | $5.7M | — | +12.43% |
| Q3 2013 | 2013-09-30 | $3.3M | −$2.9M | −46.54% | +3.83% |
| Q2 2013 | 2013-06-30 | $9.9M | $2.0M | +25.48% | +10.19% |
| Q1 2013 | 2013-03-31 | $12.2M | −$6.0M | −32.78% | +12.75% |
| Q4 2012 | 2012-12-31 | −$155,000 | $2.8M | — | −0.34% |
| Q3 2012 | 2012-09-30 | $6.2M | $7.6M | — | +6.80% |
| Q2 2012 | 2012-06-30 | $7.9M | −$1.4M | −15.13% | +8.43% |
| Q1 2012 | 2012-03-31 | $18.2M | $2.6M | +16.28% | +20.48% |
| Q4 2011 | 2011-12-31 | −$2.9M | −$7.5M | — | −4.20% |
| Q3 2011 | 2011-09-30 | −$1.4M | — | — | −1.89% |
| Q2 2011 | 2011-06-30 | $9.3M | — | — | +11.87% |
| Q1 2011 | 2011-03-31 | $15.7M | — | — | +21.08% |
| Q3 2010 | 2010-09-30 | $4.6M | — | — | +6.77% |
Medifast free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $139.3M to $1.2M, a compound annual decline of 61.05%. Medifast's latest reported quarter, Q2 2026, generated $728,000 in free cash flow, an increase of $5.5M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Medifast filings at SEC.gov ↗